Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.61 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6504402 | 0.84 | HSD11B1 (0.65) | HSD11B1EPHX2HSD17B10L3MBTL1 | |
| SCHEMBL6500873 | 0.84 | HSD11B1 (0.56) | HSD11B1EPHX1CYP2C9EPHX2HSD17B10 | |
| SCHEMBL5160289 | 0.82 | HSD11B1 (0.68) | HSD11B1EPHX1EPHX2HSD17B10L3MBTL1 | |
| SCHEMBL20545129 | 0.79 | EPHX1 (0.46) | CACNA1HEPHX1HSD17B10 | |
| SCHEMBL18851365 | 0.79 | EPHX1 (0.46) | CACNA1HEPHX1 | |
| SCHEMBL18851364 | 0.79 | EPHX1 (0.46) | CACNA1HEPHX1 | |
| SCHEMBL25827535 | 0.78 | EPHX1 (0.46) | CACNA1HEPHX1L3MBTL1 | |
| SCHEMBL7131093 | 0.78 | EPHX1 (0.45) | CACNA1HEPHX1 | |
| SCHEMBL22151747 | 0.78 | EPHX1 (0.45) | CACNA1HEPHX1 | |
| SCHEMBL337969 | 0.78 | EPHX1 (0.45) | CACNA1HEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745019-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CHENG HENGMIAO | 2005-11-24 | — | — | US | disclosed |
| WO-2005108359-A1 | NOVEL COMPOUNDS OF PROLINE AND MORPHOLINE DERIVATIVES | PFIZER INC. (US) | 2005-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261290-A1 | Novel compounds of proline and morpholine derivatives | CYP11B1, HSD11B1, CYP11B2 | HSD11B1 2/4885CACNA1H 3642/4885EPHX1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.